Do local investors make a difference?

Do local investors make a difference?

E-mail outreach, online meetings and digital data rooms have become a given when trying to finance a therapeutic innovation! So, do local or regional anchor investors matter when developing a bioinnovation ecosystem? If the local innovation is world class, would it then not attract capital from wherever available?

Sunstone, in collaboration with our local peers and as a Nordic based investor, claims to play an important role in finding, developing and financing biotherapeutic opportunities that end up attracting international investors. But do we have data  to support that claim? or should politicians and sovereign funds not care about supporting local investors – and just focus on the quality of local/regional innovation?

To understand the impact of local investors Sunstone studied Danish companies having received financings from 2010 and forward. We looked at the HQ address of the VC’s participating in Seed, Series A and subsequent rounds in Denmark. The figure below illustrates how the geographical distribution of investors changes as Danish therapeutic companies progress in financing. The 1st bar illustrates the geographic distribution of investors in Seed investments that by now are unlikely to achieve a Series A (have been trying for +4 years), the second bar shows the companies that we assume are still able to achieve a series A and the third bar the companies that actually managed to get a series A financing. The data should be interpreted with caution as it covers more than 15 years of trends in investor behavior. Nevertheless, it indicates that local investors increase the likelihood of achieving a later series A – when comparing the 1st and 3rd bar. The 4th and 5th bar illustrate how the geographical mix of investors evolve in Series A and later financings. If on average, investors invest the same amount in a financing, the data suggests that local investors play an important role in seeding companies and need to support approximately 50% of series A investments to progress local or regional innovation.

What are your thoughts? – How important are the local or regional investors to the innovation ecosystem?

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Treetop Meeting

We usually do not share updates from internal meetings - but this was too fantastic not to share. A full day meeting in the midst of branches of +100 year old oaks and beech trees overlooking Isefjorden in “the treetop huts” at Ryegaard & Trudsholm Godser. Spiced...

Hans T. Scambye joins Sunstone as Venture Partner

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini...

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

5 latest articles

Seed & Series A in Denmark

Financing a Danish Biotech company has apparently never been more challenging. Based on feedback from partnering meetings in 2025 it seems that raising Series A financing has become an unprecedented challenge. However, when looking at the available data on the...

Are Series A radically growing?

If you are in the biotech venture capital business, it’s been difficult to avoid conversations about the increasing sizes of Series A financing rounds. We’ve been hearing and reading about a revival of biotech financing, including “Biotech Financing: darkest before...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...

The VC summer dream – the Fund Returner

The VC summer dream – the Fund ReturnerSunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...

Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular,...